Bioxcel Therapeutics BTAI 深 沪
等待开盘 08-02 09:30:00 美东时间
1.3635
+0.054
+4.08%
华盛通- 最 高2.07
- 今 开1.65
- 成交量 1.05亿股
- 最 低 1.337
- 昨 收 1.31
- 总市值 825.74万
- 52周最高 13.3616
- 市盈率 静 --
- 换手率 1736.71%
- 52周最低 1.17
- 委 比 27.27%
- 总股本 605.60万
- 历史最高 1144.00
- 量 比 425.41
- 振 幅 55.95%
- 历史最低 1.337
- 每 手 1
- 风险率 3.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioXcel Completes Phase 3 Trial for BXCL501
Bioxcel Therapeutics ( ($BTAI) ) has issued an announcement. On August 1, 2025,...
08-01 19:28
BioXcel Therapeutics shares are trading higher after the company completed the last patient visit in its SERENITY at-home pivotal Phase 3 safety trial.
BioXcel Therapeutics shares are trading higher after the company completed the ...
08-01 19:02
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
BioXcel Therapeutics已向FDA提交pre-sNDA会议材料，寻求批准IGALMI®用于双相障碍或多动症患者在家治疗急性躁动。会议定于2025年8月20日举行，以确定sNDA内容格式，并确认此前达成的开发计划。公司CEO表示，进展顺利，接近完成关键III期试验，有望本季度报告结果。每年美国约有2300万在家发生的躁动 episode，但无获批疗法。
07-21 11:00
BioXcel Therapeutics Granted New U.S. Patent For IGALMI Dosing In Acute Agitation, Expanding Protection Through 2043
On July 15, 2025, BioXcel Therapeutics, Inc. announced that the United States Patent and Trademark Office had allowed U.S. Patent Application No. 18/600,419 with claims pertaining to the administration of a single dose
07-15 21:48
BioXcel Therapeutics shares are trading higher after the company received a second positive recommendation from the Data Safety Monitoring Board to continue its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia.
BioXcel Therapeutics shares are trading higher after the company received a sec...
07-02 02:08
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Raises Price Target to $8
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $3 to $8.
06-23 19:30
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
<p>BioAtla announced positive results from a Phase 2 trial of Ozuriftamab Vedotin (Oz-V) in heavily pretreated HPV+ OPSCC patients. The study showed an overall response rate (ORR) of 45% and a disease control rate (DCR) of 100%. Patients had a median of 3 prior lines of therapy, with all failing anti–PD-1 therapy and 85% failing platinum therapy. The oral abstract highlights significant antitumor activity compared to the current standard of care,...
06-02 12:00
BioXcel Therapeutics Wins Nasdaq Extension, Has Until September to Regain Listing Compliance
BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel granted the
05-27 19:04
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
DSMB recommended the continuation of the SERENITY At-Home Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia. The trial, which is fully enrolled with 200 patients, will continue without modification. Topline data is expected in Q3 2025. BXCL501 is an investigational drug for the acute treatment of agitation in at-home settings. The trial is a double-blind, placebo-controlled study...
05-27 12:01
